A previous study showed that loss-of-function mutation carriers in PALB2 increases the risk of BC by 9.5 times, compared to the non-carriers [43]; PALB2 mutations were detected in 2 out of 151 cases. This evidence concerns the gene PALB2 and breast cancer.